Skip to main content

Advertisement

SpringerLink
Log in

Prognostic significance of telomerase activity and some tumor markers in non-small cell lung cancer

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

The prognosis of non small cell lung cancer (NSCLC) has remained disappointing over the last decades even in localized stages. Numerous prognostic factors have been investigated which might select patients for additional treatment. The objective of the current study was to assess the prognostic significance of telomerase activity, serum anti-p53 antibodies (anti-p53a), c-erbB-2 and CEA in patients with NSCLC. The study included 60 patients with histological proven NSCLC besides 60 controls (30 smokers and 30 nonsmokers). Patients were divided into four stages according to their histopathology. All patients were subjected to; determination of telomerase activity by telomeric repeat amplification protocol (TRAP) assay in tumor tissue specimens and adjacent normal lung tissues, also, determination of preoperative serum anti-p53a, c-erbB-2 and CEA. Telomerase activity was detected in 40 of 60 (66.6%) of NSCLC tissue specimens using the TRAP assay. As regard the stages, telomerase activity was positive in 5 of 15 patients (33.3%) with stage I NSCLC, in 11 of 20 patients (55%) with stage II NSCLC, in 9 of 10 patients (90%) with stage III NSCLC and in all patients (100%) with stage IV NSCLC. More cases of positive telomerase activity were observed in the group with advanced disease and in the group with poorly differentiated tumors. Telomerase activity was not detected in any normal lung tissue. The concentrations of serum anti-p53a, c-erbB-2, CEA were significantly higher in patients with NSCLC in comparison to the smoker and nonsmoker controls and their levels increased according to the stage of disease. Logistic regression test showed a relation between telomerase positivity and anti- p53a but no relation with c-erbB2, CEA. Telomerase activity was detected in most of NSCLC tissues; it was detected more frequently in advanced disease than early-stage disease. Anti-p53, c-erbB-2 and CEA were significantly higher in patients with NSCLC than controls and this increment was more evident in late stages of the disease. So, these biological markers might be useful predictors of prognosis. They may be helpful in defining groups of patients with NSCLC who could benefit from adjuvant treatments, also these markers can be used as therapeutic targets.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Duarte RL, Paschoal ME. Molecular markers in lung cancer: prognostic role and relationship to smoking. J Bras Pneumol. 2006;32(1):56–65.

    Article  PubMed  Google Scholar 

  2. Borras C, Esteve JM, Vin JR, Sastre J, Vin J, Pallardo FV. Glutathione regulates telomerase activity in 3T3 fibroblasts. J Biol Chem. 2004;279:34332–5.

    Article  PubMed  CAS  Google Scholar 

  3. Gertler R, Rosenberg R, Stricker D, Friederichs J, Hoos A, Werner M, et al. Telomere Length and Human Telomerase Reverse Transcriptase expression as markers for progression and prognosis of colorectal carcinoma. J Clin Oncol. 2004;22:1807–14.

    Article  PubMed  CAS  Google Scholar 

  4. Piatyszek MA, Kim SL, Weinrich SL. Detection of telomerase activity in human cells and tumors by a telomeric repeat amplification protocol (TRAP). Methods Cell Sci. 1995;17:1–15.

    Article  Google Scholar 

  5. Iniesta P, González-Quevedo R, Morán A, García-Aranda C, de Juan C, Sánchez-Pernaute A, et al. Relationship between 3p deletions and telomerase activity in non-small-cell lung cancer: prognostic implications. Br J Cancer. 2004;90(10):1983–8.

    Article  PubMed  CAS  Google Scholar 

  6. Poposka BI, Smickova S, Crvenkovska SJ, Ivanovska BZ, Stefanovski T, Metodieva M, et al. Prognostic value of the expression of p53 in patients with non-small Cell lung cancer. Macedonian J Med Sci. 2009;2(4):335–40.

    Article  Google Scholar 

  7. Gebitekin C, Bayram AS, Tunca B, Balaban SA. Clinical significance of p53 gene mutation in T1–2 N0 non-small cell lung cancer. Asian Cardiovasc Thorac Ann. 2007;15(1):35–8.

    PubMed  Google Scholar 

  8. Schlichtholz B, Tradaniel J, Lubin R, Zalcman G, Hirsch A, Soussi T. Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. Br J Cancer. 1994;69:809–16.

    Article  PubMed  CAS  Google Scholar 

  9. Meert AP, Martin B, Paesmans M. The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literature. Br J Cancer. 2003;89:959–65.

    Article  PubMed  CAS  Google Scholar 

  10. Shigematsu H, Takahashi T, Nomura M. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res. 2005;65:1642–6.

    Article  PubMed  CAS  Google Scholar 

  11. Nakamura H, Kawasaki N, Taguchi M, Kabasawa K. Association of HER-2 overexpression with prognosis in nonsmall cell lung carcinoma: a metaanalysis. Cancer. 2005;103:1865–73.

    Article  PubMed  CAS  Google Scholar 

  12. Salgia R, David H, James EH, Evan P, Anthony E, Arthur TS. Role of serum tumor markers Ca 125 and CEA in non-small cell lung cancer. Anticancer Res. 2001;21:1241–6.

    PubMed  CAS  Google Scholar 

  13. Sawabata N, Ohta M, Takeda S. Serum carcinoembryonic antigen level in surgically resected clinical stage I patients with non-small cell lung cancer. Ann Thorac Surg. 2002;74:174–9.

    Article  PubMed  Google Scholar 

  14. Mountain CF. Revisions in the international system for staging lung cancer. Chest. 1997;111:1710–7.

    Article  PubMed  CAS  Google Scholar 

  15. Kim NW, Piatyszek MA, Prowse KR. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994;266:2011–5.

    Article  PubMed  CAS  Google Scholar 

  16. Wright WE, Shay JW, Piatyszek MA. Modification of a telomeric repeat amplification protocol (TRAP) result in increased reliability, linearity, and sensitivity. Nucleic Acids Res. 1995;23:3794–5.

    Article  PubMed  CAS  Google Scholar 

  17. Urquidi V, Tarin D, Goodison S. Role of telomerase in cell senescence and oncogenesis. Annu Rev Med. 2000;51:65–79.

    Article  PubMed  CAS  Google Scholar 

  18. Morales CP, Holt SE, Ouellette M. Absence of cancer-associated changes in human fibroblasts immortalized with telomerase. Nat Genet. 1999;21:115–8.

    Article  PubMed  CAS  Google Scholar 

  19. Hahn WC, Counter CM, Lundberg AS. Creation of human tumor cells with defined genetic elements. Nature. 1999;400:464–8.

    Article  PubMed  CAS  Google Scholar 

  20. Taga S, Osaki T, Ohgami A. Prognostic impact of telomerase activity in non–small-cell lung cancers. Ann Surg. 1999;230:715–20.

    Article  PubMed  CAS  Google Scholar 

  21. Lantuejoul S, Salon C, Soria JC, Brambilla E. Telomerase expression in lung preneoplasia and neoplasia. Int J Cancer. 2007;120:1835–41.

    Article  PubMed  CAS  Google Scholar 

  22. Blanco D, Vicent S, Fraga MF. Molecular analysis of a multistep lung cancer model induced by chronic inflammation reveals epigenetic regulation of p16 and activation of the DNA damage response pathway. Neoplasia. 2007;9:840–52.

    Article  PubMed  CAS  Google Scholar 

  23. González-Quevedo R, Iniesta P, Morán A, Juan CD, Sánchez-Pernaute A, Fernández C, et al. Cooperative role of telomerase activity and p16 expression in the prognosis of non–small-cell lung cancer. J Clin Oncol. 2002;20(1):254–62.

    Article  PubMed  Google Scholar 

  24. Targowski T, Jahnz-Rózyk K, Szkoda T, Płusa T, From S. Telomerase activity in transthoracic fine-needle biopsy aspirates from non-small cell lung cancer as prognostic factor of patients’ survival. Lung Cancer. 2008;61(1):97–103.

    Article  PubMed  Google Scholar 

  25. Chen KY, Lee LN, Yu CJ, Lee YC, Kuo SH, Yang PC. Elevation of telomerase activity positively correlates to poor prognosis of patients with non-small cell lung cancer. Cancer Lett. 2006;240(1):148–56.

    Article  PubMed  CAS  Google Scholar 

  26. Jung JH, Lee CJ, Yoo GP, Lee KY. The Expression of Telomerase Reverse Transcriptase Protein is an Independent Prognostic Marker in Early Stage Non-Small Cell Lung Carcinomas. Korean J Pathol. 2007;41:95–102.

    Google Scholar 

  27. Harley CB. Telomerase and cancer therapeutics. Nat Rev Cancer. 2008;8:167–79.

    Article  PubMed  CAS  Google Scholar 

  28. Steels E, Paesmans M, Berghmans T, Branle F, Lemaitre F, Mascaux C, et al. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J. 2001;18:705–19.

    Article  PubMed  CAS  Google Scholar 

  29. Laudanski J, Niklinska W, Burzykowski T, Chyczewski L, Niklinski J. Prognostic significance of p53 and bcl-2 abnormalities in operable non-small cell lung cancer. Eur Respir J. 2001;17:660–6.

    Article  PubMed  CAS  Google Scholar 

  30. Murray PV, Soussi T, O’Brien MER, Smith IE, Brossault S, Norton A, et al. Serum p53 antibodies: predictors of survival in small-cell lung cancer? Br J Cancer. 2000;83:1418–24.

    Article  PubMed  CAS  Google Scholar 

  31. Lai CL, Tsai CM, Tsai TT, Kuo BI, Chang KT, Fu HT, et al. Presence of serum anti-p53 antibodies is associated with pleural effusion and poor prognosis in lung cancer patients. Clin Cancer Res. 1998;4(12):3025–30.

    PubMed  CAS  Google Scholar 

  32. Ohmura Y, Aoe M, Andou A, Shimizu N. Telomerase activity and Bcl-2 expression in non-small cell lung cancer. Clin Cancer Res. 2000;6(8):2980–7.

    PubMed  CAS  Google Scholar 

  33. Maniwa Y, Yoshimura M, Obayashi C, Inaba M, Kiyooka K, Kanki M, et al. Association of p53 Gene Mutation and Telomerase Activity in Resectable Non-Small Cell. Lung Cancer Chest. 2001;120:589–94.

    CAS  Google Scholar 

  34. Perera SA, Maser RS, Xia H. Telomere dysfunction promotes genome instability and metastatic potential in a K-ras p53 mouse model of lung cancer. Carcinogenesis. 2008;29:747–53.

    Article  PubMed  CAS  Google Scholar 

  35. Abdel Salam I, Gaballa HE, Abdel Wahab N. Serum levels of epidermal growth factor and HER-2 neu in non small-cell lung cancer: prognostic correlation. Med Oncol. 2009;26(2):161–6.

    Article  PubMed  CAS  Google Scholar 

  36. Ardizzoni A, Cafferata MA, Paganuzzi M, Filiberti R, Marroni P, Neri M, et al. Study of pretreatment serum levels of HER-2/neu oncoprotein as a prognostic and predictive factor in patients with advanced nonsmall cell lung carcinoma. Cancer. 2001;92(7):1896–904.

    Article  PubMed  CAS  Google Scholar 

  37. Micke P, Georg Hengstler J, Ros R, Bittinger F, Metz T, Gebhard S, et al. c-erbB-2 Expression in small-cell lung cancer is associated with poor prognosis. Int J Cancer. 2001;15(4):469–618.

    Google Scholar 

  38. Ochiai A, Akimoto S, Kanai Y, Shibata T, Oyama T, Hirohashi S. c-erbB-2 gene product associates with catenins in human cancer cells. Biochem Biophys Res Commun. 1994;205(1):73–8.

    Article  PubMed  CAS  Google Scholar 

  39. Tateishi M, Ishida T, Mitsudomi T, Kaneko S, Sugimachi K. Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma. Eur J Cancer. 1991;27:1372–5.

    Article  PubMed  CAS  Google Scholar 

  40. Giatromanolaki A, Koukourakis MI, O’Byrne K, Kaklamanis L, Dicoglou C, Trichia E, et al. Non-small cell lung cancer: c-erbB-2 overexpression correlates with low angiogenesis and poor prognosis. Anticancer Res. 1996;16:3819–25.

    PubMed  CAS  Google Scholar 

  41. Hsu WH, Huang CS, Hsu HS, Huang WJ, Lee HC, Huang MD, et al. Preoperative serum carcinoembryonic antigen level is a prognostic factor in women with early non–small-cell lung cancer. Ann Thorac Surg. 2007;83:419–24.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Biochemistry Department, National Research Centre, Cairo, Egypt

    Maha Hashim, Magda Sayed & Nervana Samy

  2. Surgery Department, National Cancer Institute, Cairo, Egypt

    Salah Elshazly

Authors
  1. Maha Hashim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Magda Sayed
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nervana Samy
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Salah Elshazly
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nervana Samy.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hashim, M., Sayed, M., Samy, N. et al. Prognostic significance of telomerase activity and some tumor markers in non-small cell lung cancer. Med Oncol 28, 322–330 (2011). https://doi.org/10.1007/s12032-010-9444-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-010-9444-0

Keywords

Search

Navigation